Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidanc
Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates. Also, BTIG raised its price target on the stock from $190 to $195.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.